The global microfluidics market size is expected to reach around US$ 12.9 billion by 2026 and will grow at noteworthy CAGR around 17.5 % throughout the forecast period.
For system design and solution growth, the microfluidics industry offers practical implementation of tiny volumes of fluid. Microfluidics is an up-to-date technology with increased healthcare acceptability.
The report provides analysis of global Microfluidics market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
Due to the rising demand of the points of care (POC) market, the market is anticipated to increase. To interpret the data, microfluidic devices require a fraction of the sample. The implementation permitted for a lab-to-chip shift of the standard laboratory method.
This technology's potential has drawn both industry and academia to implement new sample recognition technologies and technology which can reduce mechanical mistakes. AccOn the basis of the pregnancy test, Florida Atlantic University has created a fresh approach that allows developing countries to embrace reliable and cost efficient treatment options for months, in order to store microfluidic devices without cooling.
One of the main drivers of the microfluidics industry is technological progress. An economical workshop was developed in February 2017 on the electronics, microfluidics and inkjet technology of the Stanford University School of Medicine. It's an electronic tread and an inkjet press including a microfluidic cell chamber. It can count cells, isolate cells and also collect a combination from a single cell. This instrument is scheduled for diagnostic apps.
Microfluidics in the multitude of business products have been successfully applied. Fluidigm's extremely embedded fluidic circuits provide low-cost, high-sample throughput solution for multiplex single-nucleotide polymorphism (SNP) genotyping. For nucleic acid quantitation Quanta Life utilizes droplet microfluidic techniques for digital PCRs. A microfluidic glass chip for the elevated flow fluorescent and electro-phoretically analyzed parts of protein and nucleic acid is used by the Caliper LabChip scheme.
Numerous players are attracted to the potential of this technology to expand their market share through partnership. Collaboration with other market specialists will allow powerful product portfolios to be developed and microfluid device / technology versions to be enhanced and newer. CEA Tech-Leti announced, for example, in July 2015, that it will further cooperate with Illumina, Inc. Tech-Leti and Illumina would work through this cooperation to develop digital microfluidics technology of the next generation.
Due to comprehensive implementation of technology such as the POC, In Vitro Diagnostic (IVD) was in 2018 the biggest income share on the market. Moreover in IVD microfluidics are being introduced by enterprises like Abbott, Roche Diagnostics, Cepheid and Becton, Dickinson and Company (BD). Abbott's I and Samsung LabGeoPT10 are examples of one-step tests that allow one drop of blood to test for blood glycemia.
The Medical Devices Segment, which is the most desirable characteristic in any medical device, is anticipated to experience the highest development over the forecast era. Automation saves time, quality and error risk reduction. This is essential when diagnosing treatable diseases in a careful manner. In order to further drive development, diagnostic devices are urgently needed to make care points more efficiently.
New methods that can deliver better platforms for next generation sequencing are being tested by researchers. A five-year grant from the National Science Foundation for the Centre pour la Advanced Design and Manufacture of Integrated Microfluidics (CADMIM) was obtained by the University of Illinois at Chicago in November 2018 in support of the microfluidic solution development.
In July 2016, for its next generation screening platform, Metagenomics obtained a USD 11.51 million European grant. Researchers in the Netherlands at the University of Twente are developing microfluidic equipment which are primarily involved in assisting reproductive technology. This allows for the introduction of embryos in the mother's womb by means of reservoirs and microfluidic channels after fertilization.
The increasing use of sophisticated techniques such as digital microfluidics for clinical research is increasing. The Massachusetts Institute of Technology in July 2016 designed a microspace device that tests the effect of the electric area on cancer cells. In November 2017 Dolomiten launched its new droplet-based microfluidics-based system called the Nadia single-cell platform. The scientists found that the medium and low-intensity electrical field stopped the growth of cancer cells without influencing the adjacent cells.
The material segment was resulted by polymer-based microfluidics in 2018. The most commonly used material for the manufacture and prototyping in the universities is polydimethylsiloxane (PDMS). Polymer is cost-effective and robust for studies, but PDMS is substituted with sophisticated technology with an option that offers better elasticity and resistance to stress.
The glass material is used mainly for analysis equipment manufacturing. Researchers develop new methods to mass manufacture glass microchips. The Royal Society of Chemistry released an article in November 2014. A fresh technique for manufacturing glass microchips with dry movies (DFR) was created by the scientists. Wet etching of DFR glass is a one-step method, which provides a more cost-effective alternative than standard production.
Due to increasing POC diagnostics apps, Silicon is anticipated to grow in the most rapid CAGR over the forecast era. A microfluidic device was intended by scientists in July 2016 at Tufts University in Medford, combining silk with gel in the forming process. The ground was a 3D microchannel network, with rectangular hydrogels of silk. The silk gel tolerates various differences in the environment such as pH, salinity and temperature.
The existence of leading industry leaders, the introduction of sophisticated technologies and the big amount of research aimed at increasing sample volume optimization techniques as well as the steadily rising POC diagnostics market made North America the biggest sector in the industry. In addition, powerful economic support from organisations, such as cancer and stroke, is anticipated to be used with fresh POC diagnostics for chronic diseases. For example, in July 2016, a research grant of USD 1 million from the W.M was granted to the New Jersey Technology Institute. In addition, the three-year project will create fresh manufacturing products such as topological phononic crystals, which have many different applications. In April 2016, the Koch Institute of Integrative Cancer Research awarded MIT scientists USD 300,000. The grant is intended to be used to create IllumiRNA. This microfluid unit triggers a blood droplet of cell populations.
Asia-Pacific's emerging economy, research facilities and low-cost labor are the fastest increasing industry. International players try, by incorporating their goods into APAC, to penetrate the untapped market. The winner of the awarded US $2,500 Dolomite equipment was arranged in October 2015 together with the Chemical and Biological Microwaves Society in Korea. Wearable lab-on-chip devices were presented in February 2016 by Samsung Electronics as information surveillance and handling devices for the test biomarker laboratory. The bioprocessor chip is an embedded unit which conducts all-in-one testing.
Global Microfluidics Market, By Application
Global Microfluidics Market, By Material
Global Microfluidics Market, By Geography
The market research study on “Microfluidics Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Microfluidics market segments with market dynamics and their impact. The report also covers basic technology development policies.
Key Players & Strategies
Some key market players are Caliper Life Sciences; Illumina, Inc.; Abbott Laboratories; Agilent Technologies; Cepheid; Life Technologies Corporation (acquired by Thermo Fisher Scientific, Inc.); Danaher Corporation; F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; and Fluidigm Corporation.
To reinforce their market position, companies are introducing fresh goods. Recently, the news of its future microencapsulation technologies was shared by Dolomite Microfluidics. The system can encapsulate 300,000 cells within fifteen minutes into monodypersonal microfluidic droplets. For the research biologists, the instrument should be extremely useful. NeoPrep, an automatic preparation of DNA and RNA samples, was introduced in February 2015 by Illumina, Inc. 16 samples are ready at a moment during the NeoPrep microfluidics cartridge. It is anticipated that R&D and innovation will further boost development by market players.